| Index | — | P/E | — | EPS (ttm) | -3.68 | Insider Own | 21.17% | Shs Outstand | 49.31M | Perf Week | -29.19% |
| Market Cap | 733.21M | Forward P/E | — | EPS next Y | -3.74 | Insider Trans | 0.00% | Shs Float | 37.00M | Perf Month | -48.60% |
| Enterprise Value | 360.21M | PEG | — | EPS next Q | -1.04 | Short Float | 18.39% | Perf Quarter | -49.83% | ||
| Income | -164.00M | P/S | — | EPS this Y | — | Short Ratio | 6.81 | Perf Half Y | -50.42% | ||
| Sales | 0.00 | P/B | 2.00 | EPS next Y | — | ROA | -41.48% | Short Interest | 6.81M | Perf YTD | -26.09% |
| Book/sh | 7.44 | P/C | 1.97 | EPS next 5Y | — | ROE | -50.26% | 52W High | 35.83 -58.50% | Perf Year | -20.40% |
| Cash/sh | 7.56 | P/FCF | — | EPS past 3/5Y | — | ROIC | -47.92% | 52W Low | 11.36 30.90% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 8.20% 7.87% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.84 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 14.16 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 32.13 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 14.16 | EPS Q/Q | -16.67% | SMA20 | -14.91% | Beta | 0.88 | Target Price | 25.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -39.93% | Rel Volume | 0.99 | Prev Close | 15.95 |
| Employees | 77 | LT Debt/Eq | 0.00 | Earnings | Nov 16 | SMA200 | -44.83% | Avg Volume | 1.21M | Price | 14.87 |
| IPO Date | Jan 26, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.35% — | Net Debt/EBITDA | — | Volume | 1,194,872 | Change | -6.77% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-27-26 | Reiterated | Guggenheim | Buy | $18 → $30 |
| Oct-26-26 | Reiterated | Truist Financial | Buy | $18 → $21 |
| Oct-26-26 | Reiterated | Oppenheimer | Outperform | $18 → $25 |
| Oct-08-26 | Reiterated | HC Wainwright & Co. | Buy | $47 → $27 |
| Oct-07-26 | Reiterated | BTIG | Buy | $45 → $29 |
| Oct-07-26 | Reiterated | Guggenheim | Buy | $18 |
| Oct-06-26 | Reiterated | Jefferies | $45 → $18 | |
| Aug-17-26 | Reiterated | HC Wainwright & Co. | Buy | $36 → $47 |
| May-29-26 | Reiterated | Truist Securities | Buy | $43 → $45 |
| Dec-10-25 | Initiated | BTIG on firmonertinib potential | Buy | $45 |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | |
| Selling, General and Administrative Excl. Other | 31 | 24 | 15 | 10 | — | — | |
| Research and Development | 144 | 153 | 79 | 65 | — | — | |
| Other Operating Expense | 1 | 1 | 0 | 0 | — | — | |
| Operating Income | -176 | -178 | -94 | -75 | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 11 | 14 | 5 | — | — | |
| Net Income Before Taxes | -164 | -166 | -80 | -69 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -164 | -166 | -80 | -69 | — | — | |
| Net Income From Continuing Operations | -164 | -166 | -80 | -69 | — | — | |
| Net Income | -164 | -166 | -80 | -69 | — | — | |
| EPS (Recurring) | -3.68 | -4.32 | -2.56 | -2.17 | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.68 | -4.32 | -2.56 | -2.17 | — | — | |
| EPS (Diluted) | -3.68 | -4.32 | -2.56 | -2.17 | — | — | |
| EBITDA | -164 | -166 | -80 | -69 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 48 | 38 | 31 | 32 | — | — | |
| Market Capitalization | 714 | 765 | 826 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | Dec 10 '25 | Sale | 23.37 | 555,555 | 12,983,320 | 3,929,117 | Feb 03 |
| LaChapelle Robin | Chief Operating Officer | Jul 11 '25 | Option Exercise | 2.28 | 11,153 | 25,429 | 135,736 | Jul 15 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 '24 | Option Exercise | 3.28 | 27,566 | 90,482 | 124,583 | Sep 23 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | Jan 30 '24 | Buy | 18.00 | 555,555 | 9,999,990 | 4,484,672 | Feb 01 |
| ORBIMED ADVISORS LLC | Director, 10% Owner | Jan 30 '24 | Buy | 18.00 | 222,222 | 3,999,996 | 1,513,664 | Jan 31 |
| GORDON CARL L | Director, 10% Owner | Jan 30 '24 | Buy | 18.00 | 222,222 | 3,999,996 | 1,513,664 | Jan 31 |
| HEALY JAMES | Director | Jan 30 '24 | Buy | 18.00 | 444,444 | 7,999,992 | 1,696,752 | Jan 31 |